GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), a new class of drugs that can "switch off" disease-causing genes. Its stock price reflects both the success of its already approved drugs and the high potential of this cutting-edge technology.
Share prices of companies in the market segment - Specialized pharma
Alnylam is a pioneer and leader in RNA interference (RNAi), a revolutionary technology for drug discovery. We classify the company as a member of the Specialized Pharma sector, and the chart below shows the overall performance of this segment, not just Alnylam's stock.
Broad Market Index - GURU.Markets
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi), developing drugs to treat rare genetic diseases. Its innovative platform makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Alnylam is outperforming the overall market.
Change in the price of a company, segment, and market as a whole per day
ALNY - Daily change in the company's share price Alnylam Pharmaceuticals
The daily price change for Alnylam, a leader in RNA therapeutics, demonstrates its volatility and reaction to biotech news. While the chart of these fluctuations is unspectacular, it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Alnylam Pharmaceuticals, Inc. is a pioneer in RNA interference. This chart illustrates the high volatility of the biotech sector. A comparison with ALNY's performance helps us understand how its innovative yet niche platform makes it more or less sensitive to broader industry trends.
Daily change in the price of a broad market stock, index - GURU.Markets
Alnylam Pharmaceuticals is a pioneer and leader in RNA interference (RNAi), a new class of drugs. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Alnylam's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Alnylam Pharmaceuticals
Alnylam is a pioneer in RNA interference-based drug development. Its year-over-year performance reflects the commercial success of its rare disease drugs and investor confidence in the potential of this revolutionary technology.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Alnylam Pharmaceuticals, Inc. is a pioneer in RNA interference (RNAi), a new class of drugs. The company has successfully launched several drugs to treat rare diseases. Its stock price reflects the high growth potential of its unique technology compared to the traditional pharmaceutical industry.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alnylam Pharmaceuticals is a pioneer in RNA interference, a new class of drugs. Its growth is entirely dependent on scientific advances and approvals of new drugs. It is a classic example of a biotech company whose trajectory is determined by innovation rather than macroeconomic factors, allowing it to move against the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, a pioneer in RNA interference, lives within the cycle of biotech innovation. Monthly fluctuations on the chart reflect news about clinical trials, regulatory approvals of new drugs, and sales growth for existing medications.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
This chart reflects the dynamics of the biotech sector, particularly the RNA therapeutics segment, where Alnylam is a pioneer. Its movements show how the company, with several approved drugs already in place, is proving the commercial potential of its revolutionary technology amidst the overall volatility of the sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alnylam is a pioneer and leader in RNA interference (RNAi), a revolutionary technology for creating drugs that "switch off" disease-causing genes. The chart below shows general market trends. Does Alnylam live in a world of its own, where clinical trial results and scientific breakthroughs reign supreme?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Alnylam Pharmaceuticals
Alnylam Pharmaceuticals' weekly performance is a rollercoaster ride in the biotech world. The RNA interference company's stock price has reacted sharply to clinical trial data releases and regulatory decisions, reflecting the high stakes and potential breakthroughs in treating rare diseases.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Specialty pharmaceuticals is a sector where weekly performance depends on scientific breakthroughs. News about clinical trials or regulatory approvals for one company can boost the entire segment. The chart illustrates this overall backdrop, making Alnylam's success in RNA therapeutics particularly significant.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Alnylam is a pioneer in RNA interference, developing a new class of drugs. Shares of such innovative biotechs often move independently of the market, responding to scientific data. This chart will help you understand: does Alnylam exist in its own world of clinical trials, or does the overall market environment influence its stock price?
Market capitalization of the company, segment and market as a whole
ALNY - Market capitalization of the company Alnylam Pharmaceuticals
Alnylam's market capitalization tells the story of a scientific breakthrough in RNA interference and its transformation into real-world drugs. The company's price chart reflects the long journey from research to commercialization and investors' faith in the potential of an entire platform for developing new drugs. Its dynamics reflect the market's valuation of one of the most advanced technologies in modern medicine.
ALNY - Share of the company's market capitalization Alnylam Pharmaceuticals within the market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer and leader in RNA interference (RNAi), a revolutionary drug discovery technology. Its market share reflects not its size, but the uniqueness and potential of its platform. The company's market share chart tells the story of how profound science is being translated into commercialized treatments for rare and severe diseases.
Market capitalization of the market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in RNA interference, developing a new class of drugs. The chart below shows the overall market capitalization of the biotech sector. Its volatile dynamics reflect the high risks and enormous potential rewards of scientific breakthroughs, including Alnylam's technology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Alnylam Pharmaceuticals is a pioneer in RNA interference, developing next-generation drugs. Its market capitalization is not based on current sales, but rather on investors' faith in the scientific revolution. Its performance on the overall chart demonstrates how breakthrough biotechnologies can create enormous value, changing the future of medicine.
Book value capitalization of the company, segment and market as a whole
ALNY - Book value capitalization of the company Alnylam Pharmaceuticals
Alnylam Pharmaceuticals' book value is derived from its cutting-edge research centers, patents for revolutionary RNA interference technology, and manufacturing facilities. This is tangible scientific capital, opening new horizons in medicine. How has this innovative foundation grown? The chart below clearly illustrates the dynamics of its discoveries materializing.
ALNY - Share of the company's book capitalization Alnylam Pharmaceuticals within the market segment - Specialized pharma
Alnylam creates innovative RNA-based drugs, which require unique laboratories and manufacturing facilities. The chart shows the share of these high-tech tangible assets in the pharmaceutical sector, demonstrating the physical foundation on which the company is building the medicine of the future.
Market segment balance sheet capitalization - Specialized pharma
Developing RNA drugs is primarily a scientific endeavor, but it also requires physical assets. Alnylam utilizes cutting-edge laboratories for its research and development. This makes it moderately capital-intensive compared to the biotech sector, where many competitors are even more "virtual."
Book value of all companies included in the broad market index - GURU.Markets
Alnylam's book value is not represented by its factories in the traditional sense, but by its cutting-edge research laboratories and production facilities for creating RNA interference therapies. The company's assets reflect its unique technological capital in the field of gene medicine. The chart allows us to estimate the physical weight of this biotechnology pioneer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Alnylam Pharmaceuticals
For biotech company Alnylam, a market capitalization multiple times greater than its book value reflects investor faith in its unique RNA interference platform. The market isn't evaluating laboratories, but the potential of future drugs that could transform medicine.
Market to book capitalization ratio in a market segment - Specialized pharma
Alnylam is a pioneer in RNA interference therapy. Its value is determined not by its labs, but by its unique scientific platform and patents. This chart clearly demonstrates how, in biotech, market valuation reflects investors' faith in the future success of breakthrough technologies, not their current tangible assets.
Market to book capitalization ratio for the market as a whole
Alnylam Pharmaceuticals is a pioneer in RNA interference, developing a new class of drugs. The company's market capitalization is based not on its current assets, but on the potential of its scientific platform and future drugs. This metric vividly illustrates how, in biotech, expectations and intellectual property can generate value hundreds of times greater than book value.
Debts of the company, segment and market as a whole
ALNY - Company debts Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, a pioneer in RNA interference, uses debt financing to support its expensive clinical trials and bring new drugs to market. For a growth-stage biotech, debt is a way to accelerate R&D. This chart shows how the company is investing in its scientific potential for future growth.
Market segment debts - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapeutics. This is a cutting-edge field of biotechnology that requires enormous and risky investments in research. The chart shows Alnylam's financial strategy: how it balances revenue from its initial drugs with the need to raise capital, including debt, for future development.
Market debt in general
Alnylam Pharmaceuticals is a pioneer in RNA interference therapy. Growth-stage biotech companies often incur losses while investing all their resources in research and development. This chart helps us understand how Alnylam finances its innovation activities and compares its financial model, which may be dependent on external capital, with more mature sectors of the economy.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Alnylam Pharmaceuticals
Alnylam, a biopharmaceutical company at the forefront of science, can use debt to finance expensive clinical trials and bring its drugs to market. This chart shows its financial structure. It helps investors assess the company's reliance on external financing and the risks this creates before its products become profitable.
Market segment debt to market segment book capitalization - Specialized pharma
Alnylam Pharmaceuticals, a pioneer in RNA interference therapy, is at the forefront of biotech innovation. This chart compares the company's debt to the overall market capitalization of the pharmaceutical sector. It shows how the company finances its expensive clinical trials and how much its financial position depends on future success in drug development.
Debt to book value of all companies in the market
Alnylam, a pioneer in RNA therapeutics, is at the forefront of biotechnology. This chart compares the company's debt position to its overall market capitalization. It allows one to assess how the company's financial strategy, which relies on long-term scientific development, is insulated from short-term economic cycles that impact the broader market.
P/E of the company, segment and market as a whole
P/E - Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapeutics. This chart shows the high valuation investors place on its innovative platform and potential for developing treatments for rare genetic diseases. The premium reflects confidence in future scientific breakthroughs, not current profits.
P/E of the market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapeutics, opening new horizons in the treatment of rare genetic diseases. This company is at the cutting edge of science. This chart reflects the average valuation in the specialty pharmaceutical sector, helping to understand the premium the market is willing to pay for breakthrough technologies.
P/E of the market as a whole
Alnylam Pharmaceuticals is a pioneer in RNA interference, developing a new class of drugs. Biotech valuations often take on a life of their own, depending on scientific breakthroughs. Does this chart reveal the extent to which Alnylam investors are ignoring broader market trends, betting solely on the success of its unique platform?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneer in RNA interference, developing drugs to treat rare genetic diseases. This chart reflects investor expectations for its scientific platform and the commercial success of its future drugs. It evaluates the company's ability to translate cutting-edge science into profitable therapeutic solutions.
%20P%2FE%20Alnylam%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Alnylam-Pharmaceuticals&v=1772668060854 "Chart of the company's future (projected) P/E Alnylam Pharmaceuticals")
Future (projected) P/E of the market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapeutics, pioneering a new class of drugs. This chart shows how the market views Alnylam's profitability prospects relative to the biotech sector. It reflects analyst expectations for the commercial success of its unique scientific platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772668060864 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Alnylam Pharmaceuticals is a pioneer in RNA interference, developing next-generation drugs. The company's valuation is based on the potential of its scientific platform. This market sentiment chart shows how much investors are willing to risk and invest in biotech breakthroughs that could transform medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772668060868 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneer in the field of RNA interference (RNAi), creating drugs that "switch off" disease-causing genes. This graph reflects the long and risky path from scientific discovery to commercial success. Revenue growth here indicates that its innovative therapeutic platform is proving its effectiveness and finding demand.
Profit of companies in the market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapeutics for the treatment of rare genetic diseases. This chart shows the profitability dynamics of the specialty pharmaceutical industry. Alnylam's success depends on scientific breakthroughs and drug approvals, making it a leader in one of the most innovative fields of biotech.
Overall market profit
Alnylam Pharmaceuticals is a pioneer in RNA interference, developing treatments for rare genetic diseases. Demand for its drugs is driven by medical needs, not the state of the economy. However, this graph is important, as overall prosperity influences healthcare systems and their willingness to pay for the innovative, but expensive, treatments offered by Alnylam.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), a new class of drugs. This chart shows analysts' expectations for future revenue. The forecast depends on the successful commercialization of already approved drugs and, more importantly, on positive clinical trial results for new developments in their pipeline.
%20profit%20of%20the%20company%20Alnylam%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Alnylam-Pharmaceuticals&v=1772668061028 "Graph of future (projected) profit of the company Alnylam Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) drugs, opening new approaches to treating rare diseases. The specialty pharmaceutical profit forecasts presented here reflect overall investor interest in biotech, helping to assess the potential for Alnylam's breakthrough technology to drive outperformance.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772668061049 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapeutics for rare diseases. Although demand for its drugs is not directly dependent on the economy, the overall positive backdrop reflected in the chart improves the investment climate in biotech and facilitates the funding of expensive research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772668061116 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneer in RNA interference, developing a new class of drugs. For such an innovative biotech company, this chart is crucial. It shows the enormous premium investors are paying for current sales, betting that its unique scientific platform will revolutionize the treatment of many diseases.
P/S market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapeutics, opening new approaches to treating rare genetic diseases. The company's revenue depends on the success of its innovative platform. This chart shows the average valuation in the sector, helping to understand the market premium placed on Alnylam's cutting-edge scientific developments.
P/S of the market as a whole
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), a new class of drugs for treating rare genetic diseases. The company's revenue depends on the success of its innovative scientific platform. This chart shows how the market values the revenue of a biotech company with a breakthrough technology compared to the average market valuation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), developing a new class of drugs. This chart shows investors' high estimates of future drug revenue. It reflects the market's belief in the revolutionary potential of the RNAi platform for treating rare and common diseases, promising the company tremendous growth.
%20P%2FS%20Alnylam%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Alnylam-Pharmaceuticals&v=1772668061220 "The graph of the company's future (projected) P/S Alnylam Pharmaceuticals")
Future (projected) P/S of the market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapeutics for the treatment of rare genetic diseases. This chart compares the company's estimated future sales with those of other pharmaceutical companies. It reflects market expectations for the commercial success of its drugs and the potential of its entire innovative technology platform.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772668061237 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Alnylam Pharmaceuticals is a pioneer in RNA interference, developing drugs to treat rare genetic diseases. Its success is determined by scientific breakthroughs and regulatory approvals, not by the economy. This chart shows the overall market backdrop, but Alnylam's value lies in its unique technology and potential to transform medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772668061272 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Alnylam Pharmaceuticals
This chart shows the revenue of Alnylam Pharmaceuticals, a pioneer in RNA interference. The company's revenue comes from sales of its innovative drugs for the treatment of rare genetic diseases. Revenue growth demonstrates the successful commercialization of cutting-edge scientific developments and the company's ability to carve out a niche in the treatment of diseases for which there was previously no effective therapy.
Sales of companies in the market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), a revolutionary approach to treating rare genetic diseases. The company's success depends on the approval and adoption of its unique drugs. This chart shows revenue in the specialty pharmaceuticals sector. It demonstrates the growth of the orphan drug market, where Alnylam holds a leading position thanks to its innovative technology.
Overall market sales
Alnylam Pharmaceuticals is a pioneer in RNA interference, developing treatments for rare genetic diseases. Demand for its life-saving medications is largely unaffected by short-term economic fluctuations. However, long-term economic growth, reflected in this chart, ensures funding for healthcare systems and patient access to innovative therapies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapeutics. This revenue forecast chart demonstrates analysts' confidence in the commercial potential of its innovative platform. The growth is driven by expectations of increased sales of existing drugs and the successful launch of new drugs for rare genetic diseases.
%20sales%20of%20the%20company%20Alnylam%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Alnylam-Pharmaceuticals&v=1772668061388 "Schedule of future (projected) sales of the company Alnylam Pharmaceuticals")
Future (projected) sales of companies in the market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapeutics. This cutting-edge technology enables the "silencing" of disease-causing genes. This chart shows projected revenue for the specialty pharmaceuticals segment, reflecting analysts' expectations for the implementation of new breakthrough technologies in medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772668061465 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Alnylam Pharmaceuticals is a pioneer in the field of RNA interference, developing drugs for rare diseases. Although demand for its drugs is not tied to economic cycles, the overall market situation is important. A stable economy provides funding for healthcare systems, allowing patients to access expensive, innovative treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772668061548 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), developing innovative drugs to treat rare genetic diseases. This chart shows the biotech company's journey from massive research expenditures to profitability. This growth is directly related to the successful commercial launch and growing sales of its unique drugs.
Market segment marginality - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in the development of RNA interference (RNAi) therapeutics. The success of this biotech company depends on the profitability of its unique, approved drugs. This chart shows the average profitability in the pharmaceutical sector. It serves to assess the potential for Alnylam's innovative platform to generate excess profits.
Market marginality as a whole
Alnylam Pharmaceuticals is a pioneer in RNA interference, developing drugs to treat rare diseases. The company's success is less dependent on the general economic cycles reflected in this chart. The key factor is the approval of new drugs and their introduction into clinical practice. However, the overall state of the healthcare system influences accessibility and pricing.
Employees in the company, segment and market as a whole
Number of employees in the company Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneer in RNA interference, a new class of drugs capable of "silencing" disease-causing genes. This breakthrough was made possible by scientific talent. This chart shows how the company is investing in its team of scientists and researchers to push the boundaries of modern medicine and create new treatments.
Share of the company's employees Alnylam Pharmaceuticals within the market segment - Specialized pharma
Alnylam Pharmaceuticals is a leader in the development of RNA interference therapeutics. As a biotech pioneer, its greatest asset is its scientific staff. This chart highlights its leadership in this highly specialized field, demonstrating the concentration of scientific talent it has assembled—a significant portion of all global experts working on this cutting-edge technology.
Number of employees in the market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in RNA interference, a new class of drugs for treating rare genetic diseases. This graph illustrates how a scientific breakthrough can create an entirely new niche in pharmaceuticals. The growth of its scientific and clinical staff reflects the transition from research to commercialization, requiring significant investment in manufacturing and marketing.
Number of employees in the market as a whole
Alnylam Pharmaceuticals is a pioneer in cutting-edge medicine. The growth of its scientific and clinical staff speaks not just to the success of one company, but to the expansion of an entire new field of biotechnology that requires the most talented specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals is a pioneer in RNA interference, creating revolutionary drugs. Their value lies in pure science and patents. This chart shows how the market values intellectual capital at its highest level. Each company scientist potentially generates billions of dollars in value, resulting in an astronomical per-employee ratio.
%20of%20the%20company%20Alnylam%20Pharmaceuticals%20(ALNY)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Alnylam-Pharmaceuticals-ALNY&v=1772668061755 "Chart of market capitalization per employee (in thousands of dollars) of the company Alnylam Pharmaceuticals (ALNY)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), developing drugs based on this technology. Like Regeneron, it is a pure biotech company, where all value lies in science and patents. This metric compares the market valuation per scientist/employee to the industry average. It reflects how highly the market values the potential of their unique R&D platform.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772668061759 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Alnylam Pharmaceuticals is a pioneer in RNA interference therapy, developing next-generation drugs. This chart illustrates how cutting-edge science drives value. The efforts of a relatively small team of highly qualified scientists are leading to the creation of unique drugs with enormous potential, earning the company one of the highest valuations per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772668061804 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), a new class of drugs. It's a pure biotech company. Their business involves cutting-edge science, long-term clinical trials, and, if successful, high-margin drugs for rare diseases. This chart shows the company's success in commercializing its scientific breakthroughs.
%20Chart%20Alnylam%20Pharmaceuticals%20(ALNY)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Alnylam-Pharmaceuticals-ALNY&v=1772668061819 "Company Profit Per Employee (in thousands of dollars) Chart Alnylam Pharmaceuticals (ALNY)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Alnylam is a leader in RNA interference (RNAi) R&D. This chart shows the benchmark for specialty pharma. The average profit per employee in this sector (biotech) is astronomical. It's a "blockbuster business." A single successful patent for a drug for a rare disease can generate billions, recouping all R&D.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772668061857 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Alnylam Pharmaceuticals is a pioneer in RNA interference therapy. The development of such complex drugs is the result of years of work by highly qualified scientists. This chart clearly demonstrates how cutting-edge biotechnology, where intellectual capital is the primary asset, generates colossal value per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772668061913 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals is a pioneer in RNA interference therapy, developing drugs for rare diseases. This chart illustrates the economics of biotech: the enormous revenue per employee reflects the high price and value of unique, patented drugs developed by a small team of highly skilled scientists.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Alnylam-Pharmaceuticals-ALNY&v=1772668061946 "Sales chart per company employee Alnylam Pharmaceuticals (ALNY)")
Sales per employee in the market segment - Specialized pharma
Alnylam is a biotech company, a pioneer in the field of RNA interference (RNAi). Their business is built entirely on science and the development of innovative drugs. Productivity is measured by R&D success. This chart shows the industry average per employee income. It helps assess the commercial success of Alnylam's developments compared to the industry.
Sales per employee for the market as a whole
Alnylam Pharmaceuticals is a pioneer in the field of RNA interference (RNAi), creating drugs that "switch off" disease-causing genes. This is cutting-edge science. Their business is pure R&D and sales of highly specialized drugs. This metric reflects how their team of scientists and doctors creates and brings to market products with significant added value, targeting rare diseases.
Short shares by company, segment and market as a whole
Shares shorted by company Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), creating drugs that "switch off" disease genes. This chart measures investor skepticism. Biotech bears are always risk-averse: a key drug's failure in trials or a regulatory decision could send shares dependent on a scientific breakthrough plummeting.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Alnylam-Pharmaceuticals-ALNY&v=1772668061993 "Short Shares Chart for the Company Alnylam Pharmaceuticals (ALNY)")
Shares shorted by market segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), a technology that "switches off" disease-causing genes. They are developing drugs for rare diseases. This chart shows bets against the biotech. Shorting Alnylam often reflects the high risk inherent in biotech. Investors may bet on the failure of a key drug's clinical trials or doubt the commercial success of already approved niche drugs.
Shares shorted by the overall market
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), developing drugs for rare diseases. It's a risky biotech sector. This indicator measures overall "risk appetite." When investors panic (as in the chart), they flee speculative biotechs whose valuations depend on future R&D successes, not current profits.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Alnylam Pharmaceuticals (ALNY)
Alnylam is a pioneer in RNA interference (RNAi), developing treatments for rare genetic diseases. This oscillator measures the reaction to binary events. Successful Phase 3 data for a new drug could trigger explosive growth and euphoria, pushing the indicator above 70. Conversely, a failed trial would send it crashing into oversold territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Alnylam-Pharmaceuticals-ALNY&v=1772668062052 "RSI 14 indicator chart for the company's stock Alnylam Pharmaceuticals (ALNY)")
RSI 14 Market Segment - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), creating drugs that "switch off" disease-causing genes. The RSI_14_Seg for "Specialized Pharma" reflects the overall sentiment in biotech. The chart helps us understand: is ALNY's growth reflecting faith in its breakthrough platform, or is the entire sector overbought on expectations of new discoveries?
RSI 14 for the overall market
Alnylam (ALNY) is a pioneer in RNA interference (RNAi), silencing disease-causing genes. This cutting-edge science focuses on rare (orphan) diseases. This market sentiment chart is the "noise." Their business is science and FDA approvals. In moments of panic, investors may flee "losing biotech," but their technology is a breakthrough.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ALNY (Alnylam Pharmaceuticals)
For Alnylam, a leader in RNA therapeutics, this chart reflects Wall Street's faith in its R&D pipeline. Analysts' price targets aren't so much an estimate of current sales as they are the discounted value of future blockbusters. Their consensus forecast is a bet that its unique technology will transform the treatment of rare (and other) diseases.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALNY-Alnylam-Pharmaceuticals&v=1772668062388 "A chart showing analyst consensus forecasts for the expected stock price. ALNY (Alnylam Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price ALNY (Alnylam Pharmaceuticals)
Alnylam Pharmaceuticals (ALNY) is a pioneer in RNA interference (RNAi), developing a new class of drugs to treat rare genetic diseases. This chart is a biotech barometer. It shows the difference between the price and the consensus target, reflecting analysts' confidence in the commercial success of their platform and the approval of new drugs from their R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALNY-Alnylam-Pharmaceuticals&v=1772668062403 "A chart showing the difference between the consensus forecast and the actual stock price. ALNY (Alnylam Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Alnylam is a leader in RNA interference (RNAi), a new class of drugs that "switch off" disease-causing genes. It's at the cutting edge of biotech. This chart shows analysts' general expectations for the specialty pharmaceutical sector. It reflects whether experts believe in the commercial success of this complex technology or see risks.
Analysts' consensus forecast for the overall market share price
Alnylam Pharmaceuticals is a pioneer in the field of RNA interference (RNAi), creating drugs that disable disease-causing genes. This is at the cutting edge of science. For companies like this, the overall market sentiment, visible in this chart, determines the availability of capital. In good times, investors are willing to finance Alnylam's lengthy and expensive development.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneer and leader in RNA interference (RNAi), a breakthrough technology that enables the disabling of disease-causing genes. This chart reflects the high scientific stakes involved. It measures the market valuation of their approved drugs for rare diseases and the belief that their technology can treat more common conditions (such as hypertension).
AKIMA Market Segment Index - Specialized pharma
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), a technology that enables the knockout of genes responsible for rare diseases. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Alnylam's breakthrough scientific platform differentiate it from the average biotech company?
The AKIM Index for the overall market
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi), a technology that enables the knockout of disease-causing genes. The company focuses on rare diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative biotech company, driven by science and FDA approvals, stacks up against broader economic trends that influence investor risk appetite.
